Biotech Start-ups Venture capital September 12, 2022Biotech start-ups with next-generation platform technologies—such as new therapeutic delivery methods and machine-learning-enabled drug discovery—have captured the lion’s share of recent venture-capital (VC) investment in the industry. Start-ups with these technologies attracted nearly $35 billion in VC funding from 2019 to 2021, compared with $17 billion for other therapeutics such as immunology. We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@mckinsey.com To read the article, see “What are the biotech investment themes that will shape the industry?,” June 10, 2022.